Singular Medical

Singular Medical (无双医疗) is a Chinese medical device company focused on cardiac electrophysiology and implantable devices. Qiming Venture Partners led its Series A, co-led its Series B, and has continued to invest through subsequent rounds including a ~RMB 150 million Series C in early 2025 . The company's product pipeline includes the SOLO® MA01-100 implantable cardiac monitor (ICM), which received NMPA approval in mid-2026 , as well as a cardiac conduction system sheath and lead that earned USPTO patent protection in late 2025 . Singular has been recognized in industry rankings including Zero2IPO's 2025 VENTURE50 and VBData's 2026 Future Healthcare 100 .